News

BOTOX is the first and only botulinum toxin product to be approved by the FDA to treat multiple muscle groups of the upper (elbow, wrist, fingers, and thumb)

Dyax is engaged in the development and commercialization of novel biotherapeutics for unmet medical needs. The company is developing DX-2930, a fully humanized monoclonal antibody targeting plasma kallikrein

A statistically significant improvement was demonstrated in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer. It is first phase 3 Vectibix trial

The company is now allowed to use Opdivo in combination with Yervoy (ipilimumab) to treat unresectable or metastatic melanoma across BRAF mutational status. The indication includes both BRAF-wild

Based on this review, the DSMB observed a continued acceptable safety and tolerability profile of Pyridorin in patients with overt diabetic nephropathy. NephroGenex CEO and President Pierre Legault

Oxeia’s lead program, OXE-103, uniquely targets the metabolic injury and energy crisis underlying acute concussion pathology. OXE-103 restores mitochondrial homeostasis via a well-characterized mechanism of action and may

The strategic alliance combines the strength of Optum’s clinical data set derived from electronic health records (EHRs), claims data assets and analytics with PAREXEL’s global, site-based research experience.

The financing was co-led by existing investors Entrepreneurs Fund, Heidelberg Capital Private Equity and new investor, UK based Fort Rock Capital. Existing investors Bayern Kapital and funds advised

AST-VAC2 is an innovative immunotherapy product that contains mature dendritic cells derived from pluripotent stem cells. These non-patient specific (allogeneic) AST-VAC2 cells are engineered to express a modified